DUPA(OtBu)-OH

DUPA(OtBu)-OH是一种DUPA前体。DUPA用作传递Docetaxel(DTX)的靶向基序，可用于治疗表达前列腺特异性膜抗原(PSMA)的前列腺肿瘤。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥1525.00

1220.00

- +
10mg

￥2375.00

1900.00

- +
50mg

￥5450.00

4360.00

- +
100mg

￥7637.00

6110.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajce50408
CAS: 1026987-94-9
别名: (S)-5-叔丁氧基-4-(3-((S)-1,5-二-叔丁氧基-1,5-二氧代-2-戊基)脲啶)-5-氧代戊酸
分子式: C23H40N2O9
分子量: 488.57
纯度: >98%
溶解度: DMSO : 125 mg/mL (255.85 mM)
储存: Store at -20°C
库存: 现货

Background

DUPA(OtBu)-OH is a DUPA precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.

DUPA(OtBu)-OH (DUPA precursor 17) is a 2-[3-(1,3-dicarboxypropyl)ureido]pentanedioic acid (DUPA) reagent[1]. The targeting ligand DUPA enhances the transport capability and selectivity of Paclitaxel (PTX) to tumor cells via prostate-specific membrane antigen (PSMA) mediated endocytosis. Besides, DUPA is conjugated with PTX via a disulfide bond, which facilitates the rapid and differential drug release in tumor cells[2].

DUPA-targeted Docetaxel (DTX) conjugate with longer spacer has no toxicity in major organs of treated mice[3].

[1]. Roy J, et al. DUPA conjugation of a cytotoxic indenoisoquinoline topoisomerase I inhibitor for selectiveprostate cancer cell targeting. J Med Chem. 2015 Apr 9;58(7):3094-103. [2]. Lv Q, et al. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate. Mol Pharm. 2018 May 7;15(5):1842-1852. [3]. Peng ZH, et al. Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specificmembrane antigen expressing prostate cancer. J Drug Target. 2013 Dec;21(10):968-80.